FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004350398> ?p ?o ?g. }

• W2004350398 endingPage "213" @default.
• W2004350398 startingPage "204" @default.
• W2004350398 abstract "Exposure to human serum induces the lysis of xenogeneic cells through natural antibodies and complement activation. The carbohydrate Galactose-alpha1,3-Galactose (Gal-alpha1,3-Gal) epitope, has been shown to be the principal antigenic determinant on target cells. This reaction is, therefore, particularly important for xenogeneic cell-based therapy. As a first step toward the evaluation of the impact of this phenomenon for encapsulated xenogeneic cells, we have evaluated the presence of the Gal-alpha1,3Gal epitope on two cell lines currently being used for the systemic delivery of protein in the periphery or the treatment of neurodegenerative diseases. In the second part of the study, we have tested and compared human serum and cerebrospinal fluid (CSF) for the presence of xenoreactive natural antibodies (XNAs) and their potential impact on the survival of xenogeneic cells. Fluorescence-activated cell sorting analysis indicated that baby hamster kidney (BHK) cells expressed low levels of the alpha-Gal epitope, whereas mouse myoblast C2C12 cells were extensively stained with the specific IB4-lectin. There was a direct correlation between serum killing and the level of Gal-alpha1,3-Gal epitope expression on these cells. Importantly, we showed that CSF did not lyse BHK and C2C12 cells as determined by cytotoxic crossmatch assays. The reaction was specific as the addition of soluble Gal-alpha1,3-Gal sugar to human serum effectively reduced cell killing, and the overproduction of alpha-1,3-galactosyltransferase in BHK cells significantly increased inactivation by human serum. To interfere with this antibody-antigen reaction and develop cell lines particularly suitable for cell-based therapy, we either selected C2C12 clones expressing low levels of Gal-alpha1,3-Gal or high levels of alpha-1,2-fucosyltransferase. These cells were found to be resistant to complement-mediated cytolysis. These strategies may, therefore, protect encapsulated xenogeneic cells transplanted in the periphery or the central nervous system even in an unlikely event of a blood-brain barrier breakage and the post-transplantation development of an antibody response." @default.
• W2004350398 created "2016-06-24" @default.
• W2004350398 creator A5001356149 @default.
• W2004350398 creator A5013403915 @default.
• W2004350398 creator A5013756173 @default.
• W2004350398 creator A5029516942 @default.
• W2004350398 creator A5087753311 @default.
• W2004350398 date "2003-04-14" @default.
• W2004350398 modified "2023-10-15" @default.
• W2004350398 title "Presence of Gal-α1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology" @default.
• W2004350398 cites W1515378450 @default.
• W2004350398 cites W1527876912 @default.
• W2004350398 cites W1529507538 @default.
• W2004350398 cites W1602641723 @default.
• W2004350398 cites W1732481302 @default.
• W2004350398 cites W1918960237 @default.
• W2004350398 cites W1963740016 @default.
• W2004350398 cites W1965363632 @default.
• W2004350398 cites W1965812300 @default.
• W2004350398 cites W1975980407 @default.
• W2004350398 cites W1980720988 @default.
• W2004350398 cites W1988417835 @default.
• W2004350398 cites W1990370275 @default.
• W2004350398 cites W1993934770 @default.
• W2004350398 cites W1998711519 @default.
• W2004350398 cites W1999614670 @default.
• W2004350398 cites W2000109586 @default.
• W2004350398 cites W2007251106 @default.
• W2004350398 cites W2009618456 @default.
• W2004350398 cites W2011752583 @default.
• W2004350398 cites W2024249789 @default.
• W2004350398 cites W2024711583 @default.
• W2004350398 cites W2030970982 @default.
• W2004350398 cites W2034632673 @default.
• W2004350398 cites W2034777103 @default.
• W2004350398 cites W2038061997 @default.
• W2004350398 cites W2043129543 @default.
• W2004350398 cites W2048769067 @default.
• W2004350398 cites W2049725455 @default.
• W2004350398 cites W2051250757 @default.
• W2004350398 cites W2052847242 @default.
• W2004350398 cites W2077222605 @default.
• W2004350398 cites W2079304688 @default.
• W2004350398 cites W2080224134 @default.
• W2004350398 cites W2080464780 @default.
• W2004350398 cites W2083920583 @default.
• W2004350398 cites W2090281556 @default.
• W2004350398 cites W2101316941 @default.
• W2004350398 cites W2164587556 @default.
• W2004350398 cites W2319307340 @default.
• W2004350398 cites W2331589909 @default.
• W2004350398 cites W4237305863 @default.
• W2004350398 cites W4238594062 @default.
• W2004350398 cites W4291193142 @default.
• W2004350398 doi "https://doi.org/10.1034/j.1399-3089.2003.00110.x" @default.
• W2004350398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12694540" @default.
• W2004350398 hasPublicationYear "2003" @default.
• W2004350398 type Work @default.
• W2004350398 sameAs 2004350398 @default.
• W2004350398 citedByCount "8" @default.
• W2004350398 countsByYear W20043503982013 @default.
• W2004350398 countsByYear W20043503982015 @default.
• W2004350398 countsByYear W20043503982016 @default.
• W2004350398 countsByYear W20043503982017 @default.
• W2004350398 countsByYear W20043503982020 @default.
• W2004350398 countsByYear W20043503982021 @default.
• W2004350398 crossrefType "journal-article" @default.
• W2004350398 hasAuthorship W2004350398A5001356149 @default.
• W2004350398 hasAuthorship W2004350398A5013403915 @default.
• W2004350398 hasAuthorship W2004350398A5013756173 @default.
• W2004350398 hasAuthorship W2004350398A5029516942 @default.
• W2004350398 hasAuthorship W2004350398A5087753311 @default.
• W2004350398 hasConcept C147483822 @default.
• W2004350398 hasConcept C1491633281 @default.
• W2004350398 hasConcept C153911025 @default.
• W2004350398 hasConcept C154317977 @default.
• W2004350398 hasConcept C159654299 @default.
• W2004350398 hasConcept C185592680 @default.
• W2004350398 hasConcept C195616568 @default.
• W2004350398 hasConcept C202751555 @default.
• W2004350398 hasConcept C203014093 @default.
• W2004350398 hasConcept C33263850 @default.
• W2004350398 hasConcept C55493867 @default.
• W2004350398 hasConcept C86803240 @default.
• W2004350398 hasConceptScore W2004350398C147483822 @default.
• W2004350398 hasConceptScore W2004350398C1491633281 @default.
• W2004350398 hasConceptScore W2004350398C153911025 @default.
• W2004350398 hasConceptScore W2004350398C154317977 @default.
• W2004350398 hasConceptScore W2004350398C159654299 @default.
• W2004350398 hasConceptScore W2004350398C185592680 @default.
• W2004350398 hasConceptScore W2004350398C195616568 @default.
• W2004350398 hasConceptScore W2004350398C202751555 @default.
• W2004350398 hasConceptScore W2004350398C203014093 @default.
• W2004350398 hasConceptScore W2004350398C33263850 @default.
• W2004350398 hasConceptScore W2004350398C55493867 @default.
• W2004350398 hasConceptScore W2004350398C86803240 @default.
• W2004350398 hasIssue "3" @default.
• W2004350398 hasLocation W20043503981 @default.

• next